Korro Bio, Inc.
General ticker "KRRO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $174.1M (TTM average)
Korro Bio, Inc. does not follow the US Stock Market performance with the rate: -6.8%.
Estimated limits based on current volatility of 3.6%: low 12.85$, high 13.80$
Factors to consider:
- Total employees count: 58 (-44.2%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Regulatory and compliance, Operating losses persist, Market competition, Manufacturing capacity limits, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.87$, 16.18$]
- 2026-12-31 to 2027-12-31 estimated range: [3.57$, 12.09$]
Financial Metrics affecting the KRRO estimates:
- Negative: with PPE of -0.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -102.58 <= 0.30
- Negative: negative Net income
- Negative: Inventory ratio change, % of 5.67 > 0.80
- Positive: 42.34 < Shareholder equity ratio, % of 45.32 <= 63.79
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of 57.44 > -0.65
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: Industry earnings per price (median), % of -12.84 <= 0
Short-term KRRO quotes
Long-term KRRO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $2.27MM | $6.39MM |
| Operating Expenses | $84.53MM | $94.18MM | $128.25MM |
| Operating Income | $-84.53MM | $-91.91MM | $-121.86MM |
| Non-Operating Income | $3.39MM | $8.47MM | $5.23MM |
| R&D Expense | $57.25MM | $63.64MM | $65.58MM |
| Income(Loss) | $-81.14MM | $-83.44MM | $-116.62MM |
| Taxes | $0.03MM | $0.14MM | $0.64MM |
| Net Income(Loss)* | $-81.17MM | $-83.58MM | $-117.26MM |
| Stockholders Equity | $169.91MM | $160.41MM | $51.44MM |
| Assets | $221.66MM | $226.24MM | $113.51MM |
| Operating Cash Flow | $-67.28MM | $-60.07MM | $-78.56MM |
| Capital expenditure | $7.84MM | $17.90MM | $0.52MM |
| Investing Cash Flow | $11.16MM | $-123.35MM | $43.99MM |
| Financing Cash Flow | $187.76MM | $69.36MM | $0.69MM |
| Earnings Per Share** | $-53.09 | $-9.37 | $-12.48 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.